Trial Outcomes & Findings for A Phase 1b Open-Label Study Investigating the Safety and Pharmacokinetics of Administration of Subcutaneous Blinatumomab for the Treatment of Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma (NCT NCT02961881)

Last Updated: 2024-02-02

Results Overview

The occurrence of any of the following toxicities during the DLT evaluation period was considered a DLT, if judged by the investigator to be related to the administration of blinatumomab: * Death * Any toxicity, regardless of grade, that lead to a participant's removal from the study by the investigator and/or sponsor * Persistent Common Terminology Criteria for Adverse Events (CTCAE) grade \>/= 2 non-hematologic adverse events (AEs) that were deemed intolerable by the participant or the treating physician and that did not respond to appropriate medical management within 5 days and lead to treatment discontinuation * Recurrent grade 2 seizures * All grade 3 and 4 AEs and laboratory abnormalities, which occurred during the SC administration portion of the treatment period with exceptions noted in protocol section 6.2.1.2.3.

Recruitment status

COMPLETED

Study phase

PHASE1

Target enrollment

35 participants

Primary outcome timeframe

Day 1 to Day 7 of Week 4

Results posted on

2024-02-02

Participant Flow

Of the 39 participants screened, 35 participants were enrolled at 10 centers in the United States, Europe and Australia between 18 September 2017 and 02 September 2021.

The participants underwent an initial continuous intravenous (cIV) blinatumomab run-in period (Weeks 1 to 3). The participants received subcutaneous (SC) administration at Week 4 followed by a treatment free period of 2 to 3 days. After the SC administration period, participants received cIV treatment to complete 6 weeks of therapy (Weeks 5 to 6).

Participant milestones

Participant milestones
Measure	Blinatumomab Cohort 1 The participants underwent an initial cIV blinatumomab run-in period (Weeks 1 to 3) in which doses increased each week as follows: Week 1: 9 μq/day; Week 2: 28 μq/day; and Week 3: 112 μq/day. The run-in period was followed by a 12-hour treatment free period. The participants then received 112 μq SC administrations every 12 hours (q12h) for 5 days at Week 4 followed by a treatment free period of 2 to 3 days. After the SC administration period, the participants received 112 μq/day cIV blinatumomab during Weeks 5 and 6.	Blinatumomab Cohort 2 The participants underwent an initial cIV blinatumomab run-in period (Weeks 1 to 3) in which doses increased each week as follows: Week 1: 9 μq/day; Week 2: 28 μq/day; and Week 3: 112 μq/day. The run-in period was followed by a 12-hour treatment free period. The participants then received 225 μq SC administrations q12h for 5 days at Week 4 followed by a treatment free period of 2 to 3 days. After the SC administration period, the participants received 112 μq/day cIV blinatumomab during Weeks 5 and 6.	Blinatumomab Cohort 3 The participants underwent an initial cIV blinatumomab run-in period (Weeks 1 to 3) in which doses increased each week as follows: Week 1: 9 μq/day; Week 2: 28 μq/day; and Week 3: 112 μq/day. The run-in period was followed by a 12-hour treatment free period. The participants then received 450 μq SC administrations every 24 hours (q24h) for 5 days at Week 4 followed by a treatment free period of 2 to 3 days. After the SC administration period, the participants received 112 μq/day cIV blinatumomab during Weeks 5 and 6.	Blinatumomab Cohort 4 The participants underwent an initial cIV blinatumomab run-in period (Weeks 1 to 3) in which doses increased each week as follows: Week 1: 9 μq/day; Week 2: 28 μq/day; and Week 3: 112 μq/day. The run-in period was followed by a 12-hour treatment free period. The participants then received 675 μq SC administrations q24h for 5 days at Week 4 followed by a treatment free period of 2 to 3 days. After the SC administration period, the participants received 112 μq/day cIV blinatumomab during Weeks 5 and 6.	Blinatumomab Cohort 5 The participants underwent an initial cIV blinatumomab run-in period (Weeks 1 to 3) in which doses increased each week as follows: Week 1: 9 μq/day; Week 2: 28 μq/day; and Week 3: 112 μq/day. The run-in period was followed by a 12-hour treatment free period. The participants then received 675 μq SC administrations every 48 hours (q48h) for 5 days at Week 4 followed by a treatment free period of 2 to 3 days. After the SC administration period, the participants received 112 μq/day cIV blinatumomab during Weeks 5 and 6.
Overall Study STARTED	7	8	8	6	6
Overall Study Started Week 4 SC Dosing	6	7	7	6	5
Overall Study Started Week 5-6 cIV Dosing	6	5	6	6	5
Overall Study COMPLETED	5	4	5	6	5
Overall Study NOT COMPLETED	2	4	3	0	1

Reasons for withdrawal

Reasons for withdrawal
Measure	Blinatumomab Cohort 1 The participants underwent an initial cIV blinatumomab run-in period (Weeks 1 to 3) in which doses increased each week as follows: Week 1: 9 μq/day; Week 2: 28 μq/day; and Week 3: 112 μq/day. The run-in period was followed by a 12-hour treatment free period. The participants then received 112 μq SC administrations every 12 hours (q12h) for 5 days at Week 4 followed by a treatment free period of 2 to 3 days. After the SC administration period, the participants received 112 μq/day cIV blinatumomab during Weeks 5 and 6.	Blinatumomab Cohort 2 The participants underwent an initial cIV blinatumomab run-in period (Weeks 1 to 3) in which doses increased each week as follows: Week 1: 9 μq/day; Week 2: 28 μq/day; and Week 3: 112 μq/day. The run-in period was followed by a 12-hour treatment free period. The participants then received 225 μq SC administrations q12h for 5 days at Week 4 followed by a treatment free period of 2 to 3 days. After the SC administration period, the participants received 112 μq/day cIV blinatumomab during Weeks 5 and 6.	Blinatumomab Cohort 3 The participants underwent an initial cIV blinatumomab run-in period (Weeks 1 to 3) in which doses increased each week as follows: Week 1: 9 μq/day; Week 2: 28 μq/day; and Week 3: 112 μq/day. The run-in period was followed by a 12-hour treatment free period. The participants then received 450 μq SC administrations every 24 hours (q24h) for 5 days at Week 4 followed by a treatment free period of 2 to 3 days. After the SC administration period, the participants received 112 μq/day cIV blinatumomab during Weeks 5 and 6.	Blinatumomab Cohort 5 The participants underwent an initial cIV blinatumomab run-in period (Weeks 1 to 3) in which doses increased each week as follows: Week 1: 9 μq/day; Week 2: 28 μq/day; and Week 3: 112 μq/day. The run-in period was followed by a 12-hour treatment free period. The participants then received 675 μq SC administrations every 48 hours (q48h) for 5 days at Week 4 followed by a treatment free period of 2 to 3 days. After the SC administration period, the participants received 112 μq/day cIV blinatumomab during Weeks 5 and 6.
Overall Study Adverse Event	1	2	2	1
Overall Study Participant request	0	2	0	0
Overall Study Disease progression	1	0	1	0

Baseline Characteristics

A Phase 1b Open-Label Study Investigating the Safety and Pharmacokinetics of Administration of Subcutaneous Blinatumomab for the Treatment of Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure	Blinatumomab Cohort 5 n=6 Participants The participants underwent an initial cIV blinatumomab run-in period (Weeks 1 to 3) in which doses increased each week as follows: Week 1: 9 μq/day; Week 2: 28 μq/day; and Week 3: 112 μq/day. The run-in period was followed by a 12-hour treatment free period. The participants then received 675 μq SC administrations q48h for 5 days at Week 4 followed by a treatment free period of 2 to 3 days. After the SC administration period, the participants received 112 μq/day cIV blinatumomab during Weeks 5 and 6.	Total n=35 Participants Total of all reporting groups	Blinatumomab Cohort 1 n=7 Participants The participants underwent an initial cIV blinatumomab run-in period (Weeks 1 to 3) in which doses increased each week as follows: Week 1: 9 μq/day; Week 2: 28 μq/day; and Week 3: 112 μq/day. The run-in period was followed by a 12-hour treatment free period. The participants then received 112 μq SC administrations q12h for 5 days at Week 4 followed by a treatment free period of 2 to 3 days. After the SC administration period, the participants received 112 μq/day cIV blinatumomab during Weeks 5 and 6.	Blinatumomab Cohort 2 n=8 Participants The participants underwent an initial cIV blinatumomab run-in period (Weeks 1 to 3) in which doses increased each week as follows: Week 1: 9 μq/day; Week 2: 28 μq/day; and Week 3: 112 μq/day. The run-in period was followed by a 12-hour treatment free period. The participants then received 225 μq SC administrations q12h for 5 days at Week 4 followed by a treatment free period of 2 to 3 days. After the SC administration period, the participants received 112 μq/day cIV blinatumomab during Weeks 5 and 6.	Blinatumomab Cohort 3 n=8 Participants Blinatumomab Cohort 3 The participants underwent an initial cIV blinatumomab run-in period (Weeks 1 to 3) in which doses increased each week as follows: Week 1: 9 μq/day; Week 2: 28 μq/day; and Week 3: 112 μq/day. The run-in period was followed by a 12-hour treatment free period. The participants then received 450 μq SC administrations q24h for 5 days at Week 4 followed by a treatment free period of 2 to 3 days. After the SC administration period, the participants received 112 μq/day cIV blinatumomab during Weeks 5 and 6.	Blinatumomab Cohort 4 n=6 Participants The participants underwent an initial cIV blinatumomab run-in period (Weeks 1 to 3) in which doses increased each week as follows: Week 1: 9 μq/day; Week 2: 28 μq/day; and Week 3: 112 μq/day. The run-in period was followed by a 12-hour treatment free period. The participants then received 675 μq SC administrations q24h for 5 days at Week 4 followed by a treatment free period of 2 to 3 days. After the SC administration period, the participants received 112 μq/day cIV blinatumomab during Weeks 5 and 6.
Age, Customized 18 - 64 years	5 Participants n=21 Participants	21 Participants n=8 Participants	5 Participants n=5 Participants	5 Participants n=7 Participants	3 Participants n=5 Participants	3 Participants n=4 Participants
Age, Customized 65 - 74 years	1 Participants n=21 Participants	13 Participants n=8 Participants	2 Participants n=5 Participants	2 Participants n=7 Participants	5 Participants n=5 Participants	3 Participants n=4 Participants
Age, Customized 75 - 84 years	0 Participants n=21 Participants	1 Participants n=8 Participants	0 Participants n=5 Participants	1 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants
Age, Customized ≥ 85 years	0 Participants n=21 Participants	0 Participants n=8 Participants	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants
Sex: Female, Male Female	1 Participants n=21 Participants	16 Participants n=8 Participants	3 Participants n=5 Participants	4 Participants n=7 Participants	5 Participants n=5 Participants	3 Participants n=4 Participants
Sex: Female, Male Male	5 Participants n=21 Participants	19 Participants n=8 Participants	4 Participants n=5 Participants	4 Participants n=7 Participants	3 Participants n=5 Participants	3 Participants n=4 Participants
Ethnicity (NIH/OMB) Hispanic or Latino	0 Participants n=21 Participants	2 Participants n=8 Participants	1 Participants n=5 Participants	1 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants
Ethnicity (NIH/OMB) Not Hispanic or Latino	6 Participants n=21 Participants	33 Participants n=8 Participants	6 Participants n=5 Participants	7 Participants n=7 Participants	8 Participants n=5 Participants	6 Participants n=4 Participants
Ethnicity (NIH/OMB) Unknown or Not Reported	0 Participants n=21 Participants	0 Participants n=8 Participants	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants
Race/Ethnicity, Customized American Indian or Alaska Native	0 Participants n=21 Participants	0 Participants n=8 Participants	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants
Race/Ethnicity, Customized Asian	0 Participants n=21 Participants	1 Participants n=8 Participants	0 Participants n=5 Participants	1 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants
Race/Ethnicity, Customized Black (or African American)	0 Participants n=21 Participants	1 Participants n=8 Participants	1 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants
Race/Ethnicity, Customized Multiple	0 Participants n=21 Participants	0 Participants n=8 Participants	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants
Race/Ethnicity, Customized Native Hawaiian or Other Pacific Islander	0 Participants n=21 Participants	0 Participants n=8 Participants	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants
Race/Ethnicity, Customized White	6 Participants n=21 Participants	31 Participants n=8 Participants	4 Participants n=5 Participants	7 Participants n=7 Participants	8 Participants n=5 Participants	6 Participants n=4 Participants
Race/Ethnicity, Customized Other	0 Participants n=21 Participants	2 Participants n=8 Participants	2 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants

PRIMARY outcome

Timeframe: Day 1 to Day 7 of Week 4

Population: DLT analysis set included DLT-evaluable participants who received all (q48h dosing), \>/= 4/5 (q24h dosing) or \>/= 8/9 (q12h dosing) doses of SC blinatumomab or experienced a DLT during the DLT evaluable period.

Outcome measures

Outcome measures
Measure	Blinatumomab SC Cohort 1 n=6 Participants The participants received 112 μq SC administrations q12h for 5 days at Week 4 followed by a treatment free period of 2 to 3 days.	Blinatumomab SC Cohort 2 n=6 Participants The participants received 225 μq SC administrations q12h for 5 days at Week 4 followed by a treatment free period of 2 to 3 days.	Blinatumomab SC Cohort 3 n=7 Participants The participants received 450 μq SC administrations q24h for 5 days at Week 4 followed by a treatment free period of 2 to 3 days.	Blinatumomab SC Cohort 4 n=6 Participants The participants received 675 μq SC administrations q24h for 5 days at Week 4 followed by a treatment free period of 2 to 3 days.	Blinatumomab SC Cohort 5 n=5 Participants The participants received 675 μq SC administrations q48h for 5 days at Week 4 followed by a treatment free period of 2 to 3 days.	Blinatumomab SC Cohort 5 The participants received 675 μq SC administrations q48h for 5 days at Week 4 followed by a treatment free period of 2 to 3 days.
Number of Participants With Dose Limiting-Toxicities (DLTs) After SC Administration	0 Participants	1 Participants	1 Participants	0 Participants	0 Participants	—

PRIMARY outcome

Timeframe: Day 1 to Day 7 of Week 4

All toxicities were graded using the CTCAE version 4.0: Grade 1 = mild; Grade 2 = moderate; Grade 3 = severe; Grade 4 = life-threatening; Grade 5 = fatal.

Outcome measures

Outcome measures
Measure	Blinatumomab SC Cohort 1 n=6 Participants The participants received 112 μq SC administrations q12h for 5 days at Week 4 followed by a treatment free period of 2 to 3 days.	Blinatumomab SC Cohort 2 n=6 Participants The participants received 225 μq SC administrations q12h for 5 days at Week 4 followed by a treatment free period of 2 to 3 days.	Blinatumomab SC Cohort 3 n=7 Participants The participants received 450 μq SC administrations q24h for 5 days at Week 4 followed by a treatment free period of 2 to 3 days.	Blinatumomab SC Cohort 4 n=6 Participants The participants received 675 μq SC administrations q24h for 5 days at Week 4 followed by a treatment free period of 2 to 3 days.	Blinatumomab SC Cohort 5 n=5 Participants The participants received 675 μq SC administrations q48h for 5 days at Week 4 followed by a treatment free period of 2 to 3 days.	Blinatumomab SC Cohort 5 The participants received 675 μq SC administrations q48h for 5 days at Week 4 followed by a treatment free period of 2 to 3 days.
Number of Participants With DLTs CTCAE Grade ≥ 3 After SC Administration	0 Participants	1 Participants	1 Participants	0 Participants	0 Participants	—

PRIMARY outcome

Timeframe: Day 1 to end of study (approximately 17 weeks)

Population: Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.

An AE was defined as any untoward medical occurrence in a clinical study participant. The AE did not necessarily have a causal relationship with study treatment. The definition of AEs included worsening of a pre-existing medical condition. TEAEs included AEs starting on or after first dose of investigational product and up to the end of study date. All AEs were graded using the CTCAE version 4.0: Grade 1 = mild; Grade 2 = moderate; Grade 3 = severe; Grade 4 = life-threatening; Grade 5 = fatal.

Outcome measures

Outcome measures
Measure	Blinatumomab SC Cohort 1 n=6 Participants The participants received 112 μq SC administrations q12h for 5 days at Week 4 followed by a treatment free period of 2 to 3 days.	Blinatumomab SC Cohort 2 n=7 Participants The participants received 225 μq SC administrations q12h for 5 days at Week 4 followed by a treatment free period of 2 to 3 days.	Blinatumomab SC Cohort 3 n=7 Participants The participants received 450 μq SC administrations q24h for 5 days at Week 4 followed by a treatment free period of 2 to 3 days.	Blinatumomab SC Cohort 4 n=6 Participants The participants received 675 μq SC administrations q24h for 5 days at Week 4 followed by a treatment free period of 2 to 3 days.	Blinatumomab SC Cohort 5 n=5 Participants The participants received 675 μq SC administrations q48h for 5 days at Week 4 followed by a treatment free period of 2 to 3 days.	Blinatumomab SC Cohort 5 The participants received 675 μq SC administrations q48h for 5 days at Week 4 followed by a treatment free period of 2 to 3 days.
Number of Participants With Treatment-emergent Adverse Events (TEAEs) After SC Administration Any TEAEs	2 Participants	6 Participants	6 Participants	6 Participants	4 Participants	—
Number of Participants With Treatment-emergent Adverse Events (TEAEs) After SC Administration Any TEAEs CTCAE Grade ≥ 3	1 Participants	1 Participants	2 Participants	1 Participants	0 Participants	—

SECONDARY outcome

Timeframe: Once at any timepoint during Day 2 of Weeks 1, 2, 3, 5 and 6

Population: Pharmacokinetic (PK) analyses set included all participants who received any cIV blinatumomab and had at least one PK sample. These participants were evaluated for PK unless significant protocol deviations affected the data analysis or if key dosing, dosing interruption, or sampling information was missing. Css data during cIV dosing was reported per dose level as pre-specified in statistical analysis plan (SAP) section 10.7.

Summarized as the observed concentrations collected after 5 half-lives after the start of the IV infusion of each dose (i.e., 9, 28 and 112 μg/day).

Outcome measures

Outcome measures
Measure	Blinatumomab SC Cohort 1 n=29 Participants The participants received 112 μq SC administrations q12h for 5 days at Week 4 followed by a treatment free period of 2 to 3 days.	Blinatumomab SC Cohort 2 n=31 Participants The participants received 225 μq SC administrations q12h for 5 days at Week 4 followed by a treatment free period of 2 to 3 days.	Blinatumomab SC Cohort 3 n=29 Participants The participants received 450 μq SC administrations q24h for 5 days at Week 4 followed by a treatment free period of 2 to 3 days.	Blinatumomab SC Cohort 4 n=26 Participants The participants received 675 μq SC administrations q24h for 5 days at Week 4 followed by a treatment free period of 2 to 3 days.	Blinatumomab SC Cohort 5 The participants received 675 μq SC administrations q48h for 5 days at Week 4 followed by a treatment free period of 2 to 3 days.	Blinatumomab SC Cohort 5 The participants received 675 μq SC administrations q48h for 5 days at Week 4 followed by a treatment free period of 2 to 3 days.
Steady State Serum Concentration (Css) of Blinatumomab After cIV Administration	238 pg/mL Geometric Coefficient of Variation 137	672 pg/mL Geometric Coefficient of Variation 94	2780 pg/mL Geometric Coefficient of Variation 87	2700 pg/mL Geometric Coefficient of Variation 85	—	—

SECONDARY outcome

Timeframe: Once at any timepoint during Day 2 of Weeks 1, 2, 3, 5 and 6

Population: PK analyses set included all participants who received any cIV blinatumomab and had at least one PK sample. These participants were evaluated for PK unless significant protocol deviations affected the data analysis or if key dosing, dosing interruption, or sampling information was missing. CL data prior to SC dosing was dose-normalized and reported together as pre-specified in SAP section 10.7.

Calculated as CL=R0/Css; where R0 is the infusion rate (μg/hr) and Css is the average Css. Both R0 and Css were dose-normalized to 112 μg/day for this calculation.

Outcome measures

Outcome measures
Measure	Blinatumomab SC Cohort 1 n=33 Participants The participants received 112 μq SC administrations q12h for 5 days at Week 4 followed by a treatment free period of 2 to 3 days.	Blinatumomab SC Cohort 2 n=26 Participants The participants received 225 μq SC administrations q12h for 5 days at Week 4 followed by a treatment free period of 2 to 3 days.	Blinatumomab SC Cohort 3 The participants received 450 μq SC administrations q24h for 5 days at Week 4 followed by a treatment free period of 2 to 3 days.	Blinatumomab SC Cohort 4 The participants received 675 μq SC administrations q24h for 5 days at Week 4 followed by a treatment free period of 2 to 3 days.	Blinatumomab SC Cohort 5 The participants received 675 μq SC administrations q48h for 5 days at Week 4 followed by a treatment free period of 2 to 3 days.	Blinatumomab SC Cohort 5 The participants received 675 μq SC administrations q48h for 5 days at Week 4 followed by a treatment free period of 2 to 3 days.
Systemic Clearance (CL) of Blinatumomab After cIV Administration	1.67 L/hr Geometric Coefficient of Variation 111	1.73 L/hr Geometric Coefficient of Variation 85	—	—	—	—

SECONDARY outcome

Timeframe: Week 4 Day 1 (pre-dose and 1, 2, 4, 6, 8 and 12 hours post-dose) and Week 4 Day 5 (pre-dose and 1, 2, 4, 6, 8, 12, 24 and 48 hours post-dose)

Population: PK analyses set included all participants who received any SC blinatumomab and had at least one PK sample. These participants were evaluated for PK unless significant protocol deviations affected the data analysis or if key dosing, dosing interruption, or sampling information was missing. Descriptive statistics for first SC dose of 675 μg on Week 4 Day 1 were determined using parameter estimates from participants in Cohorts 4 and 5 as pre-specified in SAP section 10.7.

Outcome measures

Outcome measures
Measure	Blinatumomab SC Cohort 1 n=6 Participants The participants received 112 μq SC administrations q12h for 5 days at Week 4 followed by a treatment free period of 2 to 3 days.	Blinatumomab SC Cohort 2 n=7 Participants The participants received 225 μq SC administrations q12h for 5 days at Week 4 followed by a treatment free period of 2 to 3 days.	Blinatumomab SC Cohort 3 n=7 Participants The participants received 450 μq SC administrations q24h for 5 days at Week 4 followed by a treatment free period of 2 to 3 days.	Blinatumomab SC Cohort 4 n=10 Participants The participants received 675 μq SC administrations q24h for 5 days at Week 4 followed by a treatment free period of 2 to 3 days.	Blinatumomab SC Cohort 5 n=6 Participants The participants received 675 μq SC administrations q48h for 5 days at Week 4 followed by a treatment free period of 2 to 3 days.	Blinatumomab SC Cohort 5 n=4 Participants The participants received 675 μq SC administrations q48h for 5 days at Week 4 followed by a treatment free period of 2 to 3 days.
Maximum Observed Concentration (Cmax) of Blinatumomab After SC Administration Week 4 Day 1	877 pg/mL Geometric Coefficient of Variation 88	1810 pg/mL Geometric Coefficient of Variation 93	2650 pg/mL Geometric Coefficient of Variation 98	4260 pg/mL Geometric Coefficient of Variation 103	—	—
Maximum Observed Concentration (Cmax) of Blinatumomab After SC Administration Week 4 Day 5	2070 pg/mL Geometric Coefficient of Variation 15	4340 pg/mL Geometric Coefficient of Variation 36	4290 pg/mL Geometric Coefficient of Variation 98	—	5690 pg/mL Geometric Coefficient of Variation 71	4340 pg/mL Geometric Coefficient of Variation 304

SECONDARY outcome

Timeframe: Week 4 Day 1 (pre-dose and 1, 2, 4, 6, 8 and 12 hours post-dose) and Week 4 Day 5 (pre-dose and 1, 2, 4, 6, 8, 12, 24 and 48 hours post-dose)

Outcome measures

Outcome measures
Measure	Blinatumomab SC Cohort 1 n=6 Participants The participants received 112 μq SC administrations q12h for 5 days at Week 4 followed by a treatment free period of 2 to 3 days.	Blinatumomab SC Cohort 2 n=7 Participants The participants received 225 μq SC administrations q12h for 5 days at Week 4 followed by a treatment free period of 2 to 3 days.	Blinatumomab SC Cohort 3 n=7 Participants The participants received 450 μq SC administrations q24h for 5 days at Week 4 followed by a treatment free period of 2 to 3 days.	Blinatumomab SC Cohort 4 n=10 Participants The participants received 675 μq SC administrations q24h for 5 days at Week 4 followed by a treatment free period of 2 to 3 days.	Blinatumomab SC Cohort 5 n=6 Participants The participants received 675 μq SC administrations q48h for 5 days at Week 4 followed by a treatment free period of 2 to 3 days.	Blinatumomab SC Cohort 5 n=4 Participants The participants received 675 μq SC administrations q48h for 5 days at Week 4 followed by a treatment free period of 2 to 3 days.
Time at Which Cmax (Tmax) Occurred of Blinatumomab After SC Administration Week 4 Day 5	2.8 hours Interval 0.0 to 8.0	4.0 hours Interval 0.0 to 6.1	7.6 hours Interval 6.0 to 12.0	—	8.0 hours Interval 4.0 to 12.0	9.5 hours Interval 2.2 to 12.0
Time at Which Cmax (Tmax) Occurred of Blinatumomab After SC Administration Week 4 Day 1	5.0 hours Interval 0.0 to 8.1	7.9 hours Interval 1.0 to 8.1	12 hours Interval 7.2 to 12.0	12 hours Interval 1.9 to 12.0	—	—

SECONDARY outcome

Timeframe: Week 4 Day 1 (pre-dose and 1, 2, 4, 6, 8 and 12 hours post-dose) and Week 4 Day 5 (pre-dose and 1, 2, 4, 6, 8, 12, 24 and 48 hours post-dose)

Population: PK analyses set included all participants who received any SC blinatumomab and had at least one PK sample. These participants were evaluated for PK unless significant protocol deviations affected the data analysis or if key dosing, dosing interruption, or sampling information was missing. At Week 4 Day 1, AUCt was only reported for SC dosing regimens in Cohorts 1 and 2 as PK sampling was taken only over the 12-hour period following dosing as pre-specified in protocol section 7.1.

Estimated using the linear trapezoidal method; where t is a dosing interval. AUC over the dosing interval, t where t is 12 hours for Cohorts 1 and 2, 24 hours for Cohorts 3 and 4, and 48 hours for Cohort 5.

Outcome measures

Outcome measures
Measure	Blinatumomab SC Cohort 1 n=6 Participants The participants received 112 μq SC administrations q12h for 5 days at Week 4 followed by a treatment free period of 2 to 3 days.	Blinatumomab SC Cohort 2 n=5 Participants The participants received 225 μq SC administrations q12h for 5 days at Week 4 followed by a treatment free period of 2 to 3 days.	Blinatumomab SC Cohort 3 n=6 Participants The participants received 450 μq SC administrations q24h for 5 days at Week 4 followed by a treatment free period of 2 to 3 days.	Blinatumomab SC Cohort 4 n=6 Participants The participants received 675 μq SC administrations q24h for 5 days at Week 4 followed by a treatment free period of 2 to 3 days.	Blinatumomab SC Cohort 5 n=4 Participants The participants received 675 μq SC administrations q48h for 5 days at Week 4 followed by a treatment free period of 2 to 3 days.	Blinatumomab SC Cohort 5 The participants received 675 μq SC administrations q48h for 5 days at Week 4 followed by a treatment free period of 2 to 3 days.
Area Under the Concentration-time Curve (AUC) of Blinatumomab After SC Administration for a Dosing Interval t (AUCt) Week 4 Day 1	6080 hr•pg/mL Geometric Coefficient of Variation 80	9430 hr•pg/mL Geometric Coefficient of Variation 40	—	—	—	—
Area Under the Concentration-time Curve (AUC) of Blinatumomab After SC Administration for a Dosing Interval t (AUCt) Week 4 Day 5	19100 hr•pg/mL Geometric Coefficient of Variation 21	40500 hr•pg/mL Geometric Coefficient of Variation 41	72000 hr•pg/mL Geometric Coefficient of Variation 92	90900 hr•pg/mL Geometric Coefficient of Variation 77	90800 hr•pg/mL Geometric Coefficient of Variation 236	—

SECONDARY outcome

Timeframe: Week 4 Day 1 (pre-dose and 1, 2, 4, 6, 8 and 12 hours post-dose) and Week 4 Day 5 (pre-dose and 1, 2, 4, 6, 8, 12, 24 and 48 hours post-dose)

Population: PK analyses set included all participants who received any SC blinatumomab and had at least one PK sample. These participants were evaluated for PK unless significant protocol deviations affected the data analysis or if key dosing, dosing interruption, or sampling information was missing. At Week 4 Day 1, Cmin was only reported for SC dosing regimens in Cohorts 1 and 2 as PK sampling was taken only over the 12-hour period following dosing as pre-specified in protocol section 7.1.

Outcome measures

Outcome measures
Measure	Blinatumomab SC Cohort 1 n=6 Participants The participants received 112 μq SC administrations q12h for 5 days at Week 4 followed by a treatment free period of 2 to 3 days.	Blinatumomab SC Cohort 2 n=6 Participants The participants received 225 μq SC administrations q12h for 5 days at Week 4 followed by a treatment free period of 2 to 3 days.	Blinatumomab SC Cohort 3 n=6 Participants The participants received 450 μq SC administrations q24h for 5 days at Week 4 followed by a treatment free period of 2 to 3 days.	Blinatumomab SC Cohort 4 n=6 Participants The participants received 675 μq SC administrations q24h for 5 days at Week 4 followed by a treatment free period of 2 to 3 days.	Blinatumomab SC Cohort 5 n=4 Participants The participants received 675 μq SC administrations q48h for 5 days at Week 4 followed by a treatment free period of 2 to 3 days.	Blinatumomab SC Cohort 5 The participants received 675 μq SC administrations q48h for 5 days at Week 4 followed by a treatment free period of 2 to 3 days.
Minimum Observed Concentration (Cmin) of Blinatumomab After SC Administration Week 4 Day 1	651 pg/mL Geometric Coefficient of Variation 93	1470 pg/mL Geometric Coefficient of Variation 101	—	—	—	—
Minimum Observed Concentration (Cmin) of Blinatumomab After SC Administration Week 4 Day 5	1290 pg/mL Geometric Coefficient of Variation 30	2550 pg/mL Geometric Coefficient of Variation 41	1950 pg/mL Geometric Coefficient of Variation 94	2130 pg/mL Geometric Coefficient of Variation 104	147 pg/mL Geometric Coefficient of Variation 66	—

SECONDARY outcome

Timeframe: Week 4 Day 5 (pre-dose and 1, 2, 4, 6, 8, 12, 24 and 48 hours post-dose)

Calculated as CL/F = Dose sc / AUCt-ss (at steady state).

Outcome measures

Outcome measures
Measure	Blinatumomab SC Cohort 1 n=6 Participants The participants received 112 μq SC administrations q12h for 5 days at Week 4 followed by a treatment free period of 2 to 3 days.	Blinatumomab SC Cohort 2 n=5 Participants The participants received 225 μq SC administrations q12h for 5 days at Week 4 followed by a treatment free period of 2 to 3 days.	Blinatumomab SC Cohort 3 n=6 Participants The participants received 450 μq SC administrations q24h for 5 days at Week 4 followed by a treatment free period of 2 to 3 days.	Blinatumomab SC Cohort 4 n=6 Participants The participants received 675 μq SC administrations q24h for 5 days at Week 4 followed by a treatment free period of 2 to 3 days.	Blinatumomab SC Cohort 5 n=4 Participants The participants received 675 μq SC administrations q48h for 5 days at Week 4 followed by a treatment free period of 2 to 3 days.	Blinatumomab SC Cohort 5 The participants received 675 μq SC administrations q48h for 5 days at Week 4 followed by a treatment free period of 2 to 3 days.
Apparent Clearance (CL/F) of Blinatumomab After SC Administration	5.85 L/hr Geometric Coefficient of Variation 21	5.55 L/hr Geometric Coefficient of Variation 41	6.25 L/hr Geometric Coefficient of Variation 92	7.43 L/hr Geometric Coefficient of Variation 77	7.43 L/hr Geometric Coefficient of Variation 236	—

SECONDARY outcome

Timeframe: Week 4 Day 5 (pre-dose and 1, 2, 4, 6, 8, 12, 24 and 48 hours post-dose)

Calculated as Vz/F=CL/F / λz, where λz was the first-order rate constant estimated via linear regression of the terminal log-linear decay phase as determined from the noncompartmental analysis.

Outcome measures

Outcome measures
Measure	Blinatumomab SC Cohort 1 n=6 Participants The participants received 112 μq SC administrations q12h for 5 days at Week 4 followed by a treatment free period of 2 to 3 days.	Blinatumomab SC Cohort 2 n=5 Participants The participants received 225 μq SC administrations q12h for 5 days at Week 4 followed by a treatment free period of 2 to 3 days.	Blinatumomab SC Cohort 3 n=3 Participants The participants received 450 μq SC administrations q24h for 5 days at Week 4 followed by a treatment free period of 2 to 3 days.	Blinatumomab SC Cohort 4 n=4 Participants The participants received 675 μq SC administrations q24h for 5 days at Week 4 followed by a treatment free period of 2 to 3 days.	Blinatumomab SC Cohort 5 n=2 Participants The participants received 675 μq SC administrations q48h for 5 days at Week 4 followed by a treatment free period of 2 to 3 days.	Blinatumomab SC Cohort 5 The participants received 675 μq SC administrations q48h for 5 days at Week 4 followed by a treatment free period of 2 to 3 days.
Volume of Distribution Based on Terminal Phase (Vz/F) of Blinatumomab After SC Administration	83.4 liters Geometric Coefficient of Variation 19	100 liters Geometric Coefficient of Variation 93	58.6 liters Geometric Coefficient of Variation 115	120 liters Geometric Coefficient of Variation 97	133 liters Geometric Coefficient of Variation 9623	—

SECONDARY outcome

Timeframe: Week 4 Day 5 (pre-dose and 1, 2, 4, 6, 8, 12, 24 and 48 hours post-dose)

Calculated as t1/2,z = ln(2) / λz.

Outcome measures

Outcome measures
Measure	Blinatumomab SC Cohort 1 n=6 Participants The participants received 112 μq SC administrations q12h for 5 days at Week 4 followed by a treatment free period of 2 to 3 days.	Blinatumomab SC Cohort 2 n=4 Participants The participants received 225 μq SC administrations q12h for 5 days at Week 4 followed by a treatment free period of 2 to 3 days.	Blinatumomab SC Cohort 3 n=3 Participants The participants received 450 μq SC administrations q24h for 5 days at Week 4 followed by a treatment free period of 2 to 3 days.	Blinatumomab SC Cohort 4 n=4 Participants The participants received 675 μq SC administrations q24h for 5 days at Week 4 followed by a treatment free period of 2 to 3 days.	Blinatumomab SC Cohort 5 n=2 Participants The participants received 675 μq SC administrations q48h for 5 days at Week 4 followed by a treatment free period of 2 to 3 days.	Blinatumomab SC Cohort 5 The participants received 675 μq SC administrations q48h for 5 days at Week 4 followed by a treatment free period of 2 to 3 days.
Terminal Half-life (t1/2,z) of Blinatumomab After SC Administration	9.87 hours Geometric Coefficient of Variation 12	10.7 hours Geometric Coefficient of Variation 22	7.30 hours Geometric Coefficient of Variation 21	11.7 hours Geometric Coefficient of Variation 30	9.20 hours Geometric Coefficient of Variation 83	—

SECONDARY outcome

Timeframe: Week 4 Day 1 (pre-dose and 1, 2, 4, 6, 8 and 12 hours post-dose) and Week 4 Day 5 (pre-dose and 1, 2, 4, 6, 8, 12, 24 and 48 hours post-dose)

Calculated as the ratio of AUCt (last SC dose; Week 4 Day 5) / AUC (first SC dose; Week 4 Day 1).

Outcome measures

Outcome measures
Measure	Blinatumomab SC Cohort 1 n=5 Participants The participants received 112 μq SC administrations q12h for 5 days at Week 4 followed by a treatment free period of 2 to 3 days.	Blinatumomab SC Cohort 2 n=2 Participants The participants received 225 μq SC administrations q12h for 5 days at Week 4 followed by a treatment free period of 2 to 3 days.	Blinatumomab SC Cohort 3 n=2 Participants The participants received 450 μq SC administrations q24h for 5 days at Week 4 followed by a treatment free period of 2 to 3 days.	Blinatumomab SC Cohort 4 n=5 Participants The participants received 675 μq SC administrations q24h for 5 days at Week 4 followed by a treatment free period of 2 to 3 days.	Blinatumomab SC Cohort 5 n=3 Participants The participants received 675 μq SC administrations q48h for 5 days at Week 4 followed by a treatment free period of 2 to 3 days.	Blinatumomab SC Cohort 5 The participants received 675 μq SC administrations q48h for 5 days at Week 4 followed by a treatment free period of 2 to 3 days.
Accumulation Ratio of Blinatumomab After SC Administration	3.25 ratio Geometric Coefficient of Variation 61	4.14 ratio Geometric Coefficient of Variation 35	2.31 ratio Geometric Coefficient of Variation 63	1.71 ratio Geometric Coefficient of Variation 109	1.01 ratio Geometric Coefficient of Variation 107	—

SECONDARY outcome

Timeframe: Week 4 Day 5 (pre-dose and 1, 2, 4, 6, 8, 12, 24 and 48 hours post-dose)

Calculated as F = (CL \* AUCt-ss) / Dose sc.

Outcome measures

Outcome measures
Measure	Blinatumomab SC Cohort 1 n=6 Participants The participants received 112 μq SC administrations q12h for 5 days at Week 4 followed by a treatment free period of 2 to 3 days.	Blinatumomab SC Cohort 2 n=5 Participants The participants received 225 μq SC administrations q12h for 5 days at Week 4 followed by a treatment free period of 2 to 3 days.	Blinatumomab SC Cohort 3 n=5 Participants The participants received 450 μq SC administrations q24h for 5 days at Week 4 followed by a treatment free period of 2 to 3 days.	Blinatumomab SC Cohort 4 n=6 Participants The participants received 675 μq SC administrations q24h for 5 days at Week 4 followed by a treatment free period of 2 to 3 days.	Blinatumomab SC Cohort 5 n=4 Participants The participants received 675 μq SC administrations q48h for 5 days at Week 4 followed by a treatment free period of 2 to 3 days.	Blinatumomab SC Cohort 5 The participants received 675 μq SC administrations q48h for 5 days at Week 4 followed by a treatment free period of 2 to 3 days.
Bioavailability (F) of SC Blinatumomab	32.1 percent bioavailability Geometric Coefficient of Variation 38	22.5 percent bioavailability Geometric Coefficient of Variation 54	33.8 percent bioavailability Geometric Coefficient of Variation 215	24.6 percent bioavailability Geometric Coefficient of Variation 53	30.2 percent bioavailability Geometric Coefficient of Variation 180	—

SECONDARY outcome

Timeframe: Day 1 to Day 7 of Week 4

Population: DLT analysis set included all DLT-evaluable participants who received all doses (q48h), at least 4/5 doses (q24h) or at least 8/9 doses (q12h) of SC blinatumomab.

The MTD was defined as the highest dose level at which \</= 1 of 6 participants experienced a DLT.

Outcome measures

Outcome measures
Measure	Blinatumomab SC Cohort 1 n=30 Participants The participants received 112 μq SC administrations q12h for 5 days at Week 4 followed by a treatment free period of 2 to 3 days.	Blinatumomab SC Cohort 2 The participants received 225 μq SC administrations q12h for 5 days at Week 4 followed by a treatment free period of 2 to 3 days.	Blinatumomab SC Cohort 3 The participants received 450 μq SC administrations q24h for 5 days at Week 4 followed by a treatment free period of 2 to 3 days.	Blinatumomab SC Cohort 4 The participants received 675 μq SC administrations q24h for 5 days at Week 4 followed by a treatment free period of 2 to 3 days.	Blinatumomab SC Cohort 5 The participants received 675 μq SC administrations q48h for 5 days at Week 4 followed by a treatment free period of 2 to 3 days.	Blinatumomab SC Cohort 5 The participants received 675 μq SC administrations q48h for 5 days at Week 4 followed by a treatment free period of 2 to 3 days.
Maximum Tolerated Dose (MTD) of SC Blinatumomab	NA μq The MTD was not reached in this study.	—	—	—	—	—

SECONDARY outcome

Timeframe: Predose at the re-start of cIV infusion (Week 5 Day 1)

Population: Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.

Outcome measures

Outcome measures
Measure	Blinatumomab SC Cohort 1 n=6 Participants The participants received 112 μq SC administrations q12h for 5 days at Week 4 followed by a treatment free period of 2 to 3 days.	Blinatumomab SC Cohort 2 n=7 Participants The participants received 225 μq SC administrations q12h for 5 days at Week 4 followed by a treatment free period of 2 to 3 days.	Blinatumomab SC Cohort 3 n=7 Participants The participants received 450 μq SC administrations q24h for 5 days at Week 4 followed by a treatment free period of 2 to 3 days.	Blinatumomab SC Cohort 4 n=6 Participants The participants received 675 μq SC administrations q24h for 5 days at Week 4 followed by a treatment free period of 2 to 3 days.	Blinatumomab SC Cohort 5 n=5 Participants The participants received 675 μq SC administrations q48h for 5 days at Week 4 followed by a treatment free period of 2 to 3 days.	Blinatumomab SC Cohort 5 The participants received 675 μq SC administrations q48h for 5 days at Week 4 followed by a treatment free period of 2 to 3 days.
Number of Participants With Anti-blinatumomab Antibody Formation After SC Administration	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	—

SECONDARY outcome

Timeframe: Day 1 to end of study (approximately 17 weeks)

Population: Full analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.

Percentage of participants achieving ORR (complete response \[CR\] + partial response \[PR\]) was determined by best overall response using Cheson criteria: * CR: disappearance of all evidence of disease. * PR: regression of measurable disease and no new sites. The 95% confidence interval (CI) was calculated using Clopper-Pearson exact CI. Participants were considered as non-responders if there was no response assessment available.

Outcome measures

Outcome measures
Measure	Blinatumomab SC Cohort 1 n=6 Participants The participants received 112 μq SC administrations q12h for 5 days at Week 4 followed by a treatment free period of 2 to 3 days.	Blinatumomab SC Cohort 2 n=7 Participants The participants received 225 μq SC administrations q12h for 5 days at Week 4 followed by a treatment free period of 2 to 3 days.	Blinatumomab SC Cohort 3 n=7 Participants The participants received 450 μq SC administrations q24h for 5 days at Week 4 followed by a treatment free period of 2 to 3 days.	Blinatumomab SC Cohort 4 n=6 Participants The participants received 675 μq SC administrations q24h for 5 days at Week 4 followed by a treatment free period of 2 to 3 days.	Blinatumomab SC Cohort 5 n=5 Participants The participants received 675 μq SC administrations q48h for 5 days at Week 4 followed by a treatment free period of 2 to 3 days.	Blinatumomab SC Cohort 5 The participants received 675 μq SC administrations q48h for 5 days at Week 4 followed by a treatment free period of 2 to 3 days.
Overall Response Rate (ORR) After SC Administration	66.7 percentage of participants Interval 22.3 to 95.7	71.4 percentage of participants Interval 29.0 to 96.3	71.4 percentage of participants Interval 29.0 to 96.3	83.3 percentage of participants Interval 35.9 to 99.6	40.0 percentage of participants Interval 5.3 to 85.3	—

Adverse Events

Blinatumomab cIV Before SC Week 1

Serious events: 5 serious events

Other events: 23 other events

Deaths: 1 deaths

Blinatumomab cIV Before SC Week 2

Serious events: 5 serious events

Other events: 22 other events

Deaths: 0 deaths

Blinatumomab cIV Before SC Week 3

Serious events: 8 serious events

Other events: 23 other events

Deaths: 0 deaths

Blinatumomab SC Cohort 1

Serious events: 0 serious events

Other events: 2 other events

Deaths: 0 deaths

Blinatumomab SC Cohort 2

Serious events: 1 serious events

Other events: 6 other events

Deaths: 0 deaths

Blinatumomab SC Cohort 3

Serious events: 1 serious events

Other events: 6 other events

Deaths: 0 deaths

Blinatumomab SC Cohort 4

Serious events: 0 serious events

Other events: 6 other events

Deaths: 0 deaths

Blinatumomab SC Cohort 5

Serious events: 0 serious events

Other events: 4 other events

Deaths: 0 deaths

Blinatumomab cIV After SC

Serious events: 10 serious events

Other events: 19 other events

Deaths: 1 deaths

Blinatumomab SC Total

Serious events: 2 serious events

Other events: 24 other events

Deaths: 0 deaths

Blinatumomab cIV Total

Serious events: 18 serious events

Other events: 34 other events

Deaths: 2 deaths

Blinatumomab SC + cIV Total

Serious events: 19 serious events

Other events: 35 other events

Deaths: 2 deaths

Serious adverse events

Serious adverse events
Measure	Blinatumomab cIV Before SC Week 1 n=35 participants at risk The participants received 9 μq/day cIV administrations during Week 1.	Blinatumomab cIV Before SC Week 2 n=34 participants at risk The participants received 28 μq/day cIV administrations during Week 2.	Blinatumomab cIV Before SC Week 3 n=33 participants at risk The participants received 112 μq/day cIV administrations during Week 3.	Blinatumomab SC Cohort 1 n=6 participants at risk The participants received 112 μq SC administrations q12h for 5 days at Week 4 followed by a treatment free period of 2 to 3 days.	Blinatumomab SC Cohort 2 n=7 participants at risk The participants received 225 μq SC administrations q12h for 5 days at Week 4 followed by a treatment free period of 2 to 3 days.	Blinatumomab SC Cohort 3 n=7 participants at risk The participants received 450 μq SC administrations q24h for 5 days at Week 4 followed by a treatment free period of 2 to 3 days.	Blinatumomab SC Cohort 4 n=6 participants at risk The participants received 675 μq SC administrations q24h for 5 days at Week 4 followed by a treatment free period of 2 to 3 days.	Blinatumomab SC Cohort 5 n=5 participants at risk The participants received 675 μq SC administrations q48h for 5 days at Week 4 followed by a treatment free period of 2 to 3 days.	Blinatumomab cIV After SC n=28 participants at risk After the SC administration period, the participants received 112 μq/day cIV blinatumomab during Weeks 5 and 6.	Blinatumomab SC Total n=31 participants at risk The participants received SC administrations for 5 days at Week 4 followed by a treatment free period of 2 to 3 days.	Blinatumomab cIV Total n=35 participants at risk The participants underwent an initial cIV blinatumomab run-in period (Weeks 1 to 3) in which doses increased each week as follows: Week 1: 9 μq/day; Week 2: 28 μq/day; and Week 3: 112 μq/day. After the SC administration period, the participants received 112 μq/day cIV blinatumomab during Weeks 5 and 6.	Blinatumomab SC + cIV Total n=35 participants at risk The participants underwent an initial cIV blinatumomab run-in period (Weeks 1 to 3) in which doses increased each week as follows: Week 1: 9 μq/day; Week 2: 28 μq/day; and Week 3: 112 μq/day. The run-in period was followed by a 12-hour treatment free period. The participants then received SC administrations for 5 days at Week 4 followed by a treatment free period of 2 to 3 days. After the SC administration period, the participants received 112 μq/day cIV blinatumomab during Weeks 5 and 6.
Blood and lymphatic system disorders Anaemia	0.00% 0/35 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/34 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/33 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/6 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/7 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/7 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/6 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/5 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	3.6% 1/28 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/31 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	2.9% 1/35 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	2.9% 1/35 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.
Blood and lymphatic system disorders Febrile neutropenia	2.9% 1/35 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/34 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/33 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/6 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/7 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/7 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/6 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/5 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/28 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/31 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	2.9% 1/35 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	2.9% 1/35 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.
Blood and lymphatic system disorders Leukopenia	0.00% 0/35 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/34 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/33 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/6 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/7 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/7 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/6 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/5 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	3.6% 1/28 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/31 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	2.9% 1/35 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	2.9% 1/35 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.
Blood and lymphatic system disorders Neutropenia	0.00% 0/35 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/34 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/33 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/6 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/7 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/7 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/6 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/5 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	3.6% 1/28 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/31 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	2.9% 1/35 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	2.9% 1/35 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.
Gastrointestinal disorders Erosive oesophagitis	0.00% 0/35 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/34 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/33 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/6 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	14.3% 1/7 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/7 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/6 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/5 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/28 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	3.2% 1/31 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/35 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	2.9% 1/35 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.
General disorders Pyrexia	0.00% 0/35 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	2.9% 1/34 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/33 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/6 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/7 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/7 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/6 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/5 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	3.6% 1/28 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/31 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	5.7% 2/35 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	5.7% 2/35 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.
Immune system disorders Cytokine release syndrome	0.00% 0/35 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/34 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	6.1% 2/33 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/6 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/7 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/7 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/6 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/5 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	7.1% 2/28 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/31 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	5.7% 2/35 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	5.7% 2/35 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.
Infections and infestations Dermo-hypodermitis	0.00% 0/35 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/34 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/33 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/6 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/7 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/7 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/6 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/5 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	3.6% 1/28 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/31 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	2.9% 1/35 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	2.9% 1/35 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.
Infections and infestations Device related sepsis	2.9% 1/35 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/34 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/33 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/6 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/7 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/7 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/6 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/5 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/28 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/31 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	2.9% 1/35 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	2.9% 1/35 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.
Infections and infestations Pneumonia	2.9% 1/35 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	2.9% 1/34 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/33 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/6 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/7 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/7 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/6 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/5 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/28 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/31 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	5.7% 2/35 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	5.7% 2/35 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.
Infections and infestations Sepsis	0.00% 0/35 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/34 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	3.0% 1/33 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/6 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/7 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/7 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/6 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/5 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	3.6% 1/28 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/31 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	5.7% 2/35 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	5.7% 2/35 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.
Investigations Platelet count decreased	2.9% 1/35 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/34 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/33 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/6 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/7 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/7 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/6 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/5 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/28 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/31 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	2.9% 1/35 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	2.9% 1/35 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Mantle cell lymphoma	2.9% 1/35 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/34 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/33 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/6 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/7 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/7 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/6 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/5 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/28 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/31 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	2.9% 1/35 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	2.9% 1/35 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Marginal zone lymphoma refractory	0.00% 0/35 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/34 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/33 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/6 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/7 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/7 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/6 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/5 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	3.6% 1/28 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/31 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	2.9% 1/35 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	2.9% 1/35 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.
Nervous system disorders Aphasia	0.00% 0/35 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/34 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/33 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/6 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	14.3% 1/7 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/7 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/6 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/5 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	3.6% 1/28 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	3.2% 1/31 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	2.9% 1/35 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	5.7% 2/35 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.
Nervous system disorders Ataxia	0.00% 0/35 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/34 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	3.0% 1/33 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/6 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/7 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/7 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/6 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/5 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/28 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/31 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	2.9% 1/35 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	2.9% 1/35 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.
Nervous system disorders Cognitive disorder	0.00% 0/35 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/34 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/33 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/6 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/7 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/7 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/6 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/5 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	7.1% 2/28 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/31 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	5.7% 2/35 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	5.7% 2/35 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.
Nervous system disorders Coordination abnormal	0.00% 0/35 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	2.9% 1/34 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/33 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/6 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/7 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/7 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/6 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/5 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/28 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/31 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	2.9% 1/35 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	2.9% 1/35 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.
Nervous system disorders Dysarthria	0.00% 0/35 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	2.9% 1/34 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/33 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/6 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/7 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/7 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/6 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/5 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/28 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/31 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	2.9% 1/35 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	2.9% 1/35 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.
Nervous system disorders Hemiparesis	0.00% 0/35 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/34 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/33 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/6 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/7 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/7 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/6 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/5 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	3.6% 1/28 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/31 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	2.9% 1/35 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	2.9% 1/35 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.
Nervous system disorders Motor dysfunction	0.00% 0/35 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	2.9% 1/34 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/33 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/6 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/7 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/7 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/6 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/5 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/28 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/31 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	2.9% 1/35 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	2.9% 1/35 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.
Nervous system disorders Nervous system disorder	0.00% 0/35 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	2.9% 1/34 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	6.1% 2/33 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/6 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/7 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/7 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/6 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/5 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	3.6% 1/28 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/31 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	11.4% 4/35 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	11.4% 4/35 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.
Nervous system disorders Neurological symptom	0.00% 0/35 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	2.9% 1/34 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/33 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/6 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/7 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/7 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/6 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/5 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/28 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/31 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	2.9% 1/35 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	2.9% 1/35 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.
Nervous system disorders Neurotoxicity	0.00% 0/35 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	2.9% 1/34 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/33 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/6 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/7 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/7 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/6 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/5 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/28 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/31 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	2.9% 1/35 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	2.9% 1/35 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.
Nervous system disorders Seizure	0.00% 0/35 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/34 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/33 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/6 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/7 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	14.3% 1/7 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/6 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/5 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/28 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	3.2% 1/31 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/35 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	2.9% 1/35 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.
Psychiatric disorders Confusional state	0.00% 0/35 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/34 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	3.0% 1/33 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/6 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/7 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/7 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/6 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/5 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/28 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/31 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	2.9% 1/35 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	2.9% 1/35 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.
Psychiatric disorders Hallucination	0.00% 0/35 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/34 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/33 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/6 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/7 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	14.3% 1/7 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/6 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/5 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/28 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	3.2% 1/31 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/35 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	2.9% 1/35 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.
Respiratory, thoracic and mediastinal disorders Pleural effusion	2.9% 1/35 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/34 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/33 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/6 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/7 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/7 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/6 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/5 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/28 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/31 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	2.9% 1/35 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	2.9% 1/35 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.
Vascular disorders Hypotension	0.00% 0/35 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/34 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	3.0% 1/33 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/6 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/7 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/7 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/6 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/5 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/28 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/31 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	2.9% 1/35 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	2.9% 1/35 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.

Other adverse events

Other adverse events
Measure	Blinatumomab cIV Before SC Week 1 n=35 participants at risk The participants received 9 μq/day cIV administrations during Week 1.	Blinatumomab cIV Before SC Week 2 n=34 participants at risk The participants received 28 μq/day cIV administrations during Week 2.	Blinatumomab cIV Before SC Week 3 n=33 participants at risk The participants received 112 μq/day cIV administrations during Week 3.	Blinatumomab SC Cohort 1 n=6 participants at risk The participants received 112 μq SC administrations q12h for 5 days at Week 4 followed by a treatment free period of 2 to 3 days.	Blinatumomab SC Cohort 2 n=7 participants at risk The participants received 225 μq SC administrations q12h for 5 days at Week 4 followed by a treatment free period of 2 to 3 days.	Blinatumomab SC Cohort 3 n=7 participants at risk The participants received 450 μq SC administrations q24h for 5 days at Week 4 followed by a treatment free period of 2 to 3 days.	Blinatumomab SC Cohort 4 n=6 participants at risk The participants received 675 μq SC administrations q24h for 5 days at Week 4 followed by a treatment free period of 2 to 3 days.	Blinatumomab SC Cohort 5 n=5 participants at risk The participants received 675 μq SC administrations q48h for 5 days at Week 4 followed by a treatment free period of 2 to 3 days.	Blinatumomab cIV After SC n=28 participants at risk After the SC administration period, the participants received 112 μq/day cIV blinatumomab during Weeks 5 and 6.	Blinatumomab SC Total n=31 participants at risk The participants received SC administrations for 5 days at Week 4 followed by a treatment free period of 2 to 3 days.	Blinatumomab cIV Total n=35 participants at risk The participants underwent an initial cIV blinatumomab run-in period (Weeks 1 to 3) in which doses increased each week as follows: Week 1: 9 μq/day; Week 2: 28 μq/day; and Week 3: 112 μq/day. After the SC administration period, the participants received 112 μq/day cIV blinatumomab during Weeks 5 and 6.	Blinatumomab SC + cIV Total n=35 participants at risk The participants underwent an initial cIV blinatumomab run-in period (Weeks 1 to 3) in which doses increased each week as follows: Week 1: 9 μq/day; Week 2: 28 μq/day; and Week 3: 112 μq/day. The run-in period was followed by a 12-hour treatment free period. The participants then received SC administrations for 5 days at Week 4 followed by a treatment free period of 2 to 3 days. After the SC administration period, the participants received 112 μq/day cIV blinatumomab during Weeks 5 and 6.
Blood and lymphatic system disorders Anaemia	5.7% 2/35 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	5.9% 2/34 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	3.0% 1/33 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/6 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	14.3% 1/7 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	14.3% 1/7 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/6 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/5 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	10.7% 3/28 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	6.5% 2/31 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	14.3% 5/35 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	17.1% 6/35 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.
Blood and lymphatic system disorders Neutropenia	0.00% 0/35 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	2.9% 1/34 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	6.1% 2/33 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/6 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/7 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/7 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	16.7% 1/6 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/5 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	21.4% 6/28 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	3.2% 1/31 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	22.9% 8/35 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	22.9% 8/35 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.
Blood and lymphatic system disorders Thrombocytopenia	5.7% 2/35 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	2.9% 1/34 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	3.0% 1/33 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/6 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/7 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	14.3% 1/7 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/6 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/5 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	3.6% 1/28 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	3.2% 1/31 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	11.4% 4/35 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	14.3% 5/35 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.
Cardiac disorders Palpitations	0.00% 0/35 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/34 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/33 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/6 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	14.3% 1/7 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/7 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/6 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/5 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/28 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	3.2% 1/31 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/35 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	2.9% 1/35 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.
Ear and labyrinth disorders Vertigo	2.9% 1/35 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/34 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	6.1% 2/33 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/6 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	28.6% 2/7 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/7 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/6 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/5 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	3.6% 1/28 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	6.5% 2/31 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	8.6% 3/35 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	8.6% 3/35 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.
Eye disorders Vision blurred	0.00% 0/35 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/34 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	3.0% 1/33 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/6 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/7 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/7 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	16.7% 1/6 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/5 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/28 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	3.2% 1/31 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	2.9% 1/35 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	5.7% 2/35 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.
Gastrointestinal disorders Abdominal pain	5.7% 2/35 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	2.9% 1/34 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	3.0% 1/33 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/6 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/7 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/7 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/6 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	20.0% 1/5 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	3.6% 1/28 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	3.2% 1/31 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	11.4% 4/35 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	11.4% 4/35 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.
Gastrointestinal disorders Abdominal pain upper	0.00% 0/35 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/34 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/33 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/6 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/7 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	14.3% 1/7 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/6 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/5 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/28 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	3.2% 1/31 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/35 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	2.9% 1/35 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.
Gastrointestinal disorders Constipation	17.1% 6/35 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	8.8% 3/34 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	12.1% 4/33 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/6 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	14.3% 1/7 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/7 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/6 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/5 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	10.7% 3/28 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	3.2% 1/31 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	37.1% 13/35 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	40.0% 14/35 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.
Gastrointestinal disorders Diarrhoea	2.9% 1/35 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	5.9% 2/34 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	6.1% 2/33 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/6 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	14.3% 1/7 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/7 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/6 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/5 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	17.9% 5/28 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	3.2% 1/31 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	22.9% 8/35 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	22.9% 8/35 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.
Gastrointestinal disorders Dyspepsia	0.00% 0/35 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/34 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/33 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/6 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/7 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/7 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/6 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/5 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	7.1% 2/28 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/31 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	5.7% 2/35 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	5.7% 2/35 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.
Gastrointestinal disorders Gastrooesophageal reflux disease	0.00% 0/35 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/34 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	6.1% 2/33 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/6 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/7 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/7 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/6 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/5 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/28 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/31 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	5.7% 2/35 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	5.7% 2/35 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.
Gastrointestinal disorders Nausea	0.00% 0/35 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	8.8% 3/34 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	6.1% 2/33 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/6 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/7 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	14.3% 1/7 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/6 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/5 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	7.1% 2/28 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	3.2% 1/31 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	14.3% 5/35 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	17.1% 6/35 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.
Gastrointestinal disorders Oesophagitis	0.00% 0/35 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/34 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/33 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/6 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	14.3% 1/7 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/7 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/6 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/5 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/28 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	3.2% 1/31 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/35 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	2.9% 1/35 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.
Gastrointestinal disorders Paraesthesia oral	0.00% 0/35 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/34 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/33 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/6 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	14.3% 1/7 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/7 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/6 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/5 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/28 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	3.2% 1/31 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/35 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	2.9% 1/35 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.
Gastrointestinal disorders Vomiting	0.00% 0/35 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	5.9% 2/34 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/33 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/6 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	14.3% 1/7 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/7 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/6 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/5 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	3.6% 1/28 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	3.2% 1/31 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	5.7% 2/35 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	8.6% 3/35 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.
General disorders Administration site erythema	0.00% 0/35 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/34 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/33 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/6 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	14.3% 1/7 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/7 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/6 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/5 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/28 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	3.2% 1/31 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/35 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	2.9% 1/35 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.
General disorders Asthenia	5.7% 2/35 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	11.8% 4/34 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	6.1% 2/33 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/6 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/7 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	14.3% 1/7 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	16.7% 1/6 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/5 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	17.9% 5/28 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	6.5% 2/31 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	20.0% 7/35 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	20.0% 7/35 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.
General disorders Fatigue	8.6% 3/35 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	5.9% 2/34 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/33 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/6 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	14.3% 1/7 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/7 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/6 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/5 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	3.6% 1/28 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	3.2% 1/31 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	14.3% 5/35 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	14.3% 5/35 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.
General disorders Mucosal inflammation	0.00% 0/35 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/34 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/33 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/6 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/7 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	14.3% 1/7 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/6 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/5 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/28 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	3.2% 1/31 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/35 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	2.9% 1/35 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.
Injury, poisoning and procedural complications Fall	0.00% 0/35 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	2.9% 1/34 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/33 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/6 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/7 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/7 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/6 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	20.0% 1/5 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	3.6% 1/28 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	3.2% 1/31 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	5.7% 2/35 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	5.7% 2/35 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.
General disorders Oedema	2.9% 1/35 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/34 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/33 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/6 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/7 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/7 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/6 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/5 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	3.6% 1/28 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/31 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	5.7% 2/35 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	5.7% 2/35 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.
General disorders Oedema peripheral	0.00% 0/35 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	2.9% 1/34 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/33 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/6 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/7 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	14.3% 1/7 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/6 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/5 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	10.7% 3/28 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	3.2% 1/31 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	11.4% 4/35 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	11.4% 4/35 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.
General disorders Pyrexia	20.0% 7/35 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	8.8% 3/34 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	33.3% 11/33 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	16.7% 1/6 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/7 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	14.3% 1/7 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/6 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/5 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	14.3% 4/28 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	6.5% 2/31 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	48.6% 17/35 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	51.4% 18/35 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.
Immune system disorders Cytokine release syndrome	5.7% 2/35 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	2.9% 1/34 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	3.0% 1/33 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/6 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	14.3% 1/7 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/7 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	16.7% 1/6 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	40.0% 2/5 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/28 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	12.9% 4/31 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	11.4% 4/35 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	17.1% 6/35 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.
Infections and infestations Cytomegalovirus infection	0.00% 0/35 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/34 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/33 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/6 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/7 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/7 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/6 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/5 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	7.1% 2/28 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/31 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	5.7% 2/35 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	5.7% 2/35 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.
Infections and infestations Device related infection	0.00% 0/35 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/34 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/33 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/6 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	14.3% 1/7 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/7 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/6 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/5 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/28 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	3.2% 1/31 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/35 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	2.9% 1/35 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.
Infections and infestations Escherichia infection	0.00% 0/35 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/34 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/33 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/6 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/7 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/7 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/6 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	20.0% 1/5 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/28 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	3.2% 1/31 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/35 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	2.9% 1/35 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.
Infections and infestations Mucosal infection	0.00% 0/35 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/34 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/33 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/6 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/7 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/7 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/6 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	20.0% 1/5 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/28 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	3.2% 1/31 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/35 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	2.9% 1/35 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.
Infections and infestations Nasopharyngitis	0.00% 0/35 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/34 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/33 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/6 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/7 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/7 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/6 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/5 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	7.1% 2/28 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/31 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	5.7% 2/35 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	5.7% 2/35 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.
Infections and infestations Oral herpes	2.9% 1/35 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/34 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	3.0% 1/33 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/6 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/7 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/7 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/6 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/5 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/28 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/31 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	5.7% 2/35 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	5.7% 2/35 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.
Infections and infestations Respiratory tract infection	2.9% 1/35 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/34 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/33 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/6 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/7 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/7 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/6 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/5 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	3.6% 1/28 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/31 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	5.7% 2/35 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	5.7% 2/35 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.
Injury, poisoning and procedural complications Infusion related reaction	0.00% 0/35 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	5.9% 2/34 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/33 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/6 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/7 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/7 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/6 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/5 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/28 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/31 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	5.7% 2/35 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	5.7% 2/35 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.
Investigations Platelet count decreased	2.9% 1/35 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/34 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	6.1% 2/33 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/6 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/7 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/7 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/6 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/5 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	3.6% 1/28 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/31 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	11.4% 4/35 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	11.4% 4/35 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.
Injury, poisoning and procedural complications Skin laceration	0.00% 0/35 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/34 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/33 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/6 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/7 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/7 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/6 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	20.0% 1/5 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/28 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	3.2% 1/31 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/35 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	2.9% 1/35 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.
Investigations Alanine aminotransferase increased	5.7% 2/35 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/34 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/33 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/6 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	14.3% 1/7 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/7 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/6 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/5 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/28 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	3.2% 1/31 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	5.7% 2/35 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	8.6% 3/35 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.
Investigations Aspartate aminotransferase increased	2.9% 1/35 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/34 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	6.1% 2/33 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/6 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/7 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/7 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/6 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/5 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/28 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/31 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	5.7% 2/35 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	5.7% 2/35 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.
Investigations Blood alkaline phosphatase increased	2.9% 1/35 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	2.9% 1/34 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	3.0% 1/33 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/6 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/7 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/7 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/6 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/5 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/28 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/31 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	8.6% 3/35 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	8.6% 3/35 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.
Investigations Body temperature increased	0.00% 0/35 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/34 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/33 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/6 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/7 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/7 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/6 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	20.0% 1/5 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/28 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	3.2% 1/31 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/35 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	2.9% 1/35 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.
Investigations Weight decreased	0.00% 0/35 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/34 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	3.0% 1/33 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/6 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/7 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/7 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/6 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/5 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	3.6% 1/28 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/31 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	5.7% 2/35 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	5.7% 2/35 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.
Metabolism and nutrition disorders Decreased appetite	0.00% 0/35 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	2.9% 1/34 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	3.0% 1/33 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/6 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/7 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/7 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/6 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/5 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	3.6% 1/28 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/31 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	8.6% 3/35 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	8.6% 3/35 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.
Metabolism and nutrition disorders Folate deficiency	0.00% 0/35 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/34 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/33 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/6 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/7 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/7 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	16.7% 1/6 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/5 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/28 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	3.2% 1/31 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/35 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	2.9% 1/35 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.
Metabolism and nutrition disorders Hyperglycaemia	2.9% 1/35 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/34 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	3.0% 1/33 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	16.7% 1/6 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/7 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/7 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/6 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/5 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	7.1% 2/28 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	3.2% 1/31 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	5.7% 2/35 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	5.7% 2/35 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.
Metabolism and nutrition disorders Hyperkalaemia	2.9% 1/35 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/34 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	3.0% 1/33 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/6 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/7 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/7 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/6 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/5 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/28 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/31 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	5.7% 2/35 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	5.7% 2/35 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.
Metabolism and nutrition disorders Hypocalcaemia	0.00% 0/35 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	2.9% 1/34 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/33 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/6 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	14.3% 1/7 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/7 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/6 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/5 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	3.6% 1/28 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	3.2% 1/31 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	5.7% 2/35 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	5.7% 2/35 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.
Metabolism and nutrition disorders Hypokalaemia	0.00% 0/35 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	2.9% 1/34 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/33 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/6 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	28.6% 2/7 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/7 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/6 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/5 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/28 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	6.5% 2/31 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	2.9% 1/35 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	8.6% 3/35 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.
Metabolism and nutrition disorders Hyponatraemia	0.00% 0/35 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/34 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	9.1% 3/33 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/6 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/7 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	14.3% 1/7 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/6 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/5 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/28 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	3.2% 1/31 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	8.6% 3/35 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	8.6% 3/35 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.
Metabolism and nutrition disorders Steroid diabetes	0.00% 0/35 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/34 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/33 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/6 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/7 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/7 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/6 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/5 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	7.1% 2/28 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/31 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	5.7% 2/35 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	5.7% 2/35 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.
Musculoskeletal and connective tissue disorders Arthralgia	5.7% 2/35 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	2.9% 1/34 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/33 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/6 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/7 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/7 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	16.7% 1/6 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/5 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	3.6% 1/28 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	3.2% 1/31 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	11.4% 4/35 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	14.3% 5/35 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.
Musculoskeletal and connective tissue disorders Back pain	2.9% 1/35 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	2.9% 1/34 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	3.0% 1/33 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/6 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/7 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	14.3% 1/7 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/6 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/5 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	7.1% 2/28 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	3.2% 1/31 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	11.4% 4/35 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	14.3% 5/35 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.
Musculoskeletal and connective tissue disorders Bone pain	2.9% 1/35 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	5.9% 2/34 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	3.0% 1/33 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/6 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/7 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/7 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/6 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/5 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	3.6% 1/28 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/31 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	14.3% 5/35 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	14.3% 5/35 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.
Musculoskeletal and connective tissue disorders Muscle spasms	0.00% 0/35 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/34 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	3.0% 1/33 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/6 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/7 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/7 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/6 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	20.0% 1/5 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	10.7% 3/28 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	3.2% 1/31 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	11.4% 4/35 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	14.3% 5/35 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.
Musculoskeletal and connective tissue disorders Myalgia	2.9% 1/35 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/34 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	3.0% 1/33 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/6 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/7 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/7 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/6 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/5 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	7.1% 2/28 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/31 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	8.6% 3/35 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	8.6% 3/35 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.
Musculoskeletal and connective tissue disorders Pain in extremity	2.9% 1/35 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/34 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	6.1% 2/33 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/6 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/7 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/7 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/6 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/5 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	7.1% 2/28 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/31 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	14.3% 5/35 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	14.3% 5/35 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.
Nervous system disorders Aphasia	0.00% 0/35 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/34 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	3.0% 1/33 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/6 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/7 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	28.6% 2/7 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/6 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/5 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	3.6% 1/28 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	6.5% 2/31 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	5.7% 2/35 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	8.6% 3/35 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.
Nervous system disorders Cognitive disorder	0.00% 0/35 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/34 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	6.1% 2/33 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	16.7% 1/6 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/7 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	14.3% 1/7 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/6 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/5 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	7.1% 2/28 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	6.5% 2/31 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	5.7% 2/35 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	5.7% 2/35 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.
Nervous system disorders Disturbance in attention	0.00% 0/35 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/34 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	3.0% 1/33 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	16.7% 1/6 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/7 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/7 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/6 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/5 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/28 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	3.2% 1/31 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	2.9% 1/35 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	2.9% 1/35 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.
Nervous system disorders Dizziness	2.9% 1/35 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	5.9% 2/34 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	9.1% 3/33 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/6 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/7 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/7 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/6 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/5 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/28 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/31 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	8.6% 3/35 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	8.6% 3/35 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.
Nervous system disorders Dysarthria	0.00% 0/35 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/34 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	3.0% 1/33 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/6 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/7 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/7 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/6 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/5 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	3.6% 1/28 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/31 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	5.7% 2/35 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	5.7% 2/35 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.
Nervous system disorders Dysgraphia	0.00% 0/35 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/34 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	3.0% 1/33 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/6 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/7 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/7 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/6 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/5 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	7.1% 2/28 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/31 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	8.6% 3/35 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	8.6% 3/35 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.
Nervous system disorders Encephalopathy	0.00% 0/35 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/34 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	3.0% 1/33 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/6 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	14.3% 1/7 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/7 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/6 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/5 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/28 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	3.2% 1/31 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	2.9% 1/35 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	5.7% 2/35 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.
Nervous system disorders Headache	11.4% 4/35 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	8.8% 3/34 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	18.2% 6/33 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/6 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	28.6% 2/7 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	14.3% 1/7 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/6 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/5 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	25.0% 7/28 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	9.7% 3/31 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	42.9% 15/35 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	45.7% 16/35 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.
Nervous system disorders Nervous system disorder	0.00% 0/35 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/34 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	9.1% 3/33 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/6 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/7 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/7 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/6 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	20.0% 1/5 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	3.6% 1/28 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	3.2% 1/31 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	8.6% 3/35 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	11.4% 4/35 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.
Nervous system disorders Neurotoxicity	8.6% 3/35 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	2.9% 1/34 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	9.1% 3/33 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	16.7% 1/6 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	14.3% 1/7 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/7 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	33.3% 2/6 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/5 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	7.1% 2/28 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	12.9% 4/31 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	14.3% 5/35 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	20.0% 7/35 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.
Nervous system disorders Paraesthesia	0.00% 0/35 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/34 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	6.1% 2/33 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/6 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	14.3% 1/7 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/7 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/6 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/5 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	3.6% 1/28 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	3.2% 1/31 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	5.7% 2/35 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	5.7% 2/35 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.
Nervous system disorders Subdural hygroma	0.00% 0/35 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/34 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/33 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/6 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/7 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	14.3% 1/7 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/6 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/5 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/28 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	3.2% 1/31 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/35 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	2.9% 1/35 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.
Nervous system disorders Tremor	11.4% 4/35 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	2.9% 1/34 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	27.3% 9/33 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/6 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/7 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/7 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	33.3% 2/6 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/5 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	14.3% 4/28 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	6.5% 2/31 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	34.3% 12/35 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	34.3% 12/35 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.
Psychiatric disorders Agitation	0.00% 0/35 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/34 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/33 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/6 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	14.3% 1/7 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/7 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/6 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/5 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/28 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	3.2% 1/31 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/35 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	2.9% 1/35 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.
Psychiatric disorders Anxiety	2.9% 1/35 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	2.9% 1/34 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/33 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/6 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/7 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/7 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/6 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/5 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/28 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/31 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	5.7% 2/35 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	5.7% 2/35 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.
Psychiatric disorders Confusional state	2.9% 1/35 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/34 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	6.1% 2/33 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/6 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	14.3% 1/7 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/7 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/6 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/5 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/28 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	3.2% 1/31 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	5.7% 2/35 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	5.7% 2/35 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.
Psychiatric disorders Insomnia	8.6% 3/35 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	5.9% 2/34 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/33 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/6 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	14.3% 1/7 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	14.3% 1/7 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	16.7% 1/6 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/5 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	7.1% 2/28 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	9.7% 3/31 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	20.0% 7/35 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	25.7% 9/35 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.
Psychiatric disorders Irritability	0.00% 0/35 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/34 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/33 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/6 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	14.3% 1/7 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/7 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/6 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/5 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/28 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	3.2% 1/31 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/35 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	2.9% 1/35 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.
Respiratory, thoracic and mediastinal disorders Dysphonia	0.00% 0/35 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/34 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/33 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/6 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/7 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/7 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/6 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	20.0% 1/5 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/28 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	3.2% 1/31 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/35 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	2.9% 1/35 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.
Respiratory, thoracic and mediastinal disorders Dyspnoea	0.00% 0/35 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	2.9% 1/34 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/33 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/6 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/7 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/7 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/6 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/5 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	3.6% 1/28 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/31 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	5.7% 2/35 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	5.7% 2/35 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.
Respiratory, thoracic and mediastinal disorders Oropharyngeal pain	2.9% 1/35 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/34 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/33 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/6 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/7 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/7 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/6 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/5 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	7.1% 2/28 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/31 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	8.6% 3/35 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	8.6% 3/35 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.
Skin and subcutaneous tissue disorders Erythema	5.7% 2/35 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	2.9% 1/34 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	3.0% 1/33 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/6 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/7 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/7 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	16.7% 1/6 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/5 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	3.6% 1/28 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	3.2% 1/31 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	5.7% 2/35 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	8.6% 3/35 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.
Skin and subcutaneous tissue disorders Pruritus	0.00% 0/35 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/34 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/33 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/6 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/7 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/7 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/6 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/5 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	7.1% 2/28 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/31 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	5.7% 2/35 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	5.7% 2/35 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.
Skin and subcutaneous tissue disorders Rash	0.00% 0/35 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/34 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/33 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/6 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/7 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/7 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/6 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/5 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	7.1% 2/28 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/31 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	5.7% 2/35 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	5.7% 2/35 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.
Skin and subcutaneous tissue disorders Skin reaction	0.00% 0/35 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/34 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/33 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/6 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/7 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	14.3% 1/7 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/6 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/5 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/28 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	3.2% 1/31 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/35 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	2.9% 1/35 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.
Surgical and medical procedures Astringent therapy	0.00% 0/35 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	2.9% 1/34 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/33 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/6 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/7 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/7 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/6 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/5 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	3.6% 1/28 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/31 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	5.7% 2/35 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	5.7% 2/35 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.
Vascular disorders Hypertension	0.00% 0/35 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/34 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/33 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/6 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/7 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/7 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/6 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	20.0% 1/5 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/28 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	3.2% 1/31 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	0.00% 0/35 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.	2.9% 1/35 • Day 1 to end of study (approximately 17 weeks) Safety analysis set included participants that were enrolled and received at least 1 dose of blinatumomab.

Additional Information

Study Director

Amgen Inc.

Phone: 866-572-6436

Email: [email protected]

Results disclosure agreements

Principal investigator is a sponsor employee The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.
Publication restrictions are in place

Restriction type: OTHER